Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient Blinatumomab in MRD+ B-precursor ALL
NCT04506086Phase 4Terminated
- Sponsor
- Amgen
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Started Aug 2021; status: terminated.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04506086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506086.